Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less ...

In studies published so far, GLP-1 receptor agonists appear to be beneficial for the treatment of glaucoma, according to a review published in Cureus.“GLP-1 RAs exert both protective and adverse ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are expected to increase around the world in the coming years.

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Experts explain whether Lasik or lens implants affect your risk, and how a hair strand-like microshunt could reduce reliance on lifelong eye drops for patients.

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Glaucoma causes vision loss by damaging the optic nerve. This leads to loss of peripheral vision and eventually blindness. The damage to the optic nerve is multifactorial, but increased ocular ...

Ahead of World Glaucoma Day on March 12, we spoke to respected ophthalmologist Dr Yavische Reddy about some common questions ...

Three studies presented at the American Glaucoma Society meeting demonstrated the potential benefit of NCX 470 in patients with glaucoma.NCX 470 (Nicox) is a nitric oxide-donating bimatoprost eye drop ...